Infectious Disease Control

Sino Innovation Lab Partners with MASSPHOTON to Launch World-Leading Air Sterilizer, Helping to Curb the Spread of Germs

HONG KONG, Sept. 11, 2024 /PRNewswire/ -- The experience of the COVID-19 pandemic has heightened global awareness of air quality and indoor environmental safety like never before. MASSPHOTON and Sino Innovation Lab have joined forces to launch an innovative medical-grade air sterilizer aimed at ...

2024-09-11 16:32 2214

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA.  SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...

2024-09-11 14:25 1998

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays

-  Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. -  Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. -  Nature Awards to lead the application and eva...

2024-09-02 21:00 3209

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...

2024-08-28 17:29 2028

Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

-  Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay -  Designed to detect four viruses at once using multiplex PCR technology -  Utilize dual internal controls to ensure highly reliable test results -  Pledges to supply assays meeting the needs of respective countries SE...

2024-08-26 21:00 3368

Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution

Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coati...

2024-08-06 21:00 2686

PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY

DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...

2024-08-06 20:00 2455

Pfizer's First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong

* The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B has been approved by health authorities inHong Kong and Macau earlier, and is available inHong Kong this month (July 2024) * Helps fight against RSV in older adults aged 60 and above and infants (throu...

2024-07-18 14:41 2284

Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore

Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease SINGAPORE, July 18, 2024 /PRNewswire/ -- With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the ge...

2024-07-18 13:45 2423

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 2408

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...

2024-06-07 19:00 3602

HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]

* Arexvy has been approved by the Health Sciences Authority (HSA) of Singapore for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.[2] * Arexvy is 94.6% efficacious in prevent...

2024-05-16 10:00 2858

Animal Quarantine Service Uncovers Foreign National Attempting to Bring Livestock Products into Japan Illegally

TOKYO, May 15, 2024 /PRNewswire/ -- Last year, the Animal Quarantine Service (AQS) uncovered a foreign national who illegally brought meat such as sausages containing pork, which are prohibited from being imported toJapan from overseas, intoTokyo International Airport, and recently there was a ca...

2024-05-15 15:00 3600

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China

SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced that NEFECON®, a delayed rel...

2024-05-14 21:41 3084

Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong

A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal Immunization) * The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B disease through two seasons has been approved by Hong Kong Depa...

2024-05-08 16:14 1995

INTREPID Alliance Landscape of Promising Antivirals in Clinical Development Reveals Gaps in Global Defense Against Potential Future Pandemics

Detailed scientific analysis of antiviral pipeline identifies most promising clinical compounds aligned with 100 Days Mission global preparedness recommendations CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Building on its commitment to identify strengths and gaps in the R&D pipeline for ant...

2024-04-29 12:00 1767

Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year onApril 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger...

2024-04-26 12:39 2336

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...

2024-04-25 21:41 2166

Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19

Legacy coronavirus biochemistry was overlooked that governs spike protein toxicity, key morbidities, risk factors and therapeutic responses SALT LAKE CITY, April 22, 2024 /PRNewswire/ -- TrialSite News features a paper published today in Viruses (Basel), authored by an international team of resea...

2024-04-22 19:52 1895

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue vi...

2024-04-19 13:17 3078
1234567 ... 43

Week's Top Stories